OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries May 21, 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors Apr 24, 2019
OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer Apr 23, 2019
OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center Apr 17, 2019
OncoSec's KOL Symposium Sheds New Light on the Importance of IL-12 Use Via OncoSec's Technology and Provides Updates on TAVO's Clinical Progress Apr 8, 2019
OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting Apr 2, 2019
